StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.2
Power Rank trend -> Rising
07/08/2024 11:33:00 EST
Catalent Inc (CTLT)
Industry: Drug Manufacturers - Specialty & Generic
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, CTLT has been trading in a range between $56.50 and $54.82 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
CTLT is trading below resistance at $59.82, about 5% to the upside. There is support at $56.45 -1% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Catalent Inc $CTLT entered a Green zone 10 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $50.93, a potential down side of -10.22% from the recent price of 56.73. The stock is trading 6.12% (potential upside) below its 52 week high of $60.20 and 78.4 % (potential downside) above its 52 week low of $31.80 - based on the recent price.
Company Summary
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health.
News
| 7 Stocks' Profit Growth Will Blow Past Nvidia's This Quarter Nvidia's profit is growing fast, but not the fastest in the S&P 500. Not by a long shot, say stock analysts. Source: Investors Business Daily Mon, 01 Jul 2024 08:00:55 -0400 Sentiment: Neutral |
| Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million. Source: Benzinga Fri, 21 Jun 2024 13:52:17 -0400 Sentiment: Positive |
| Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report? Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? Source: Zacks Investment Research Fri, 07 Jun 2024 12:36:33 -0400 Sentiment: Positive |
| Catalent stockholders approve deal with Novo Holdings Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk. Source: Reuters Wed, 29 May 2024 09:21:41 -0400 Sentiment: Positive |
| Catalent Stockholders Approve Transaction with Novo Holdings SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”). “Today's outcome represents. Source: Business Wire Wed, 29 May 2024 09:07:00 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 60.2 52 Week Low: 31.8001 Beta: 1.161 50 Day MA: 55.636 200 Day MA: 50.0401 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.154 Qtr Revenue Growth YOY: 0.036 Forward PE: 37.8788 Trailing PE: 0